000623 · SZSE · China
jlaod.comFinancials as of FY2024 · latest on file
Holds Chinese government licenses to produce traditional herbal medicine formulas that only its own practitioners know how to make correctly.
Jilin Aodong Pharmaceutical Group holds NMPA drug registration certificates for traditional Chinese medicine formulations, where each certificate locks in a specific set of herbal inputs, a preparation facility, and the exact method demonstrated during approval. Because those methods were demonstrated by master practitioners who know how to match variable seasonal and geographic herb harvests to the fixed standard the certificate requires, the registration and the practitioners are effectively inseparable — a competitor can build a compliant factory, but replicating the registered method means rerunning a multi-year NMPA approval process with practitioners capable of the same assessment steps, which cannot be purchased outright. This also caps how far the company itself can grow, since adding production lines cannot substitute for the number of practitioners available to assess incoming herb batches across multiple provincial supply regions at once. The whole structure depends on NMPA continuing to accept traditional-method demonstration as the basis for registration renewal — if regulators shift to requiring Western-standard clinical trials, the existing certificates would need re-validation under a protocol the practitioner-based process was never built to satisfy.
How does this company make money?
The company sells finished pharmaceutical products — both traditional herbal medicines and conventional drugs — to Chinese hospitals, clinics, and pharmacies through domestic distribution networks, earning revenue on each unit sold. It also sells Traditional Chinese Medicine products to international buyers who specifically want authenticated TCM formulations.
What makes this company hard to replace?
Any new manufacturer trying to enter the market faces a multi-year NMPA approval process before they can legally sell a competing product. Practitioners at Chinese hospitals are familiar with how specific formulations behave — and those characteristics differ between manufacturers — so switching means relearning. The company also has established relationships with Chinese hospital procurement systems that already favor known TCM suppliers, making it hard for a newcomer to get onto approved lists.
What limits this company?
The company can only produce as many distinct medicines at any one time as it has master practitioners available to assess variable herb harvests. Adding more production lines does not help if there is no one qualified to judge whether a given herb shipment from Sichuan or Yunnan meets the registered standard.
What does this company depend on?
The company cannot operate without NMPA drug registration certificates for both its TCM and chemical drug products. It also depends on traditional Chinese medicinal herb suppliers spread across multiple provinces, chemical API suppliers for its conventional pharmaceutical products, specialized TCM processing equipment for herbal extraction and concentration, and Good Manufacturing Practice certification for its facilities in China.
Who depends on this company?
Chinese hospitals and clinics use the company's TCM formulations in standard treatment protocols — if supply stopped, they would have no direct replacement. International markets buying authenticated Traditional Chinese Medicine products would be forced to substitute non-traditional alternatives. Chinese pharmacies that stock both traditional and modern medicines would face gaps in their product range that would disrupt how they put together treatment plans for patients.
How does this company scale?
Standard chemical drug manufacturing and conventional tablet or capsule production can grow by adding production lines and automated equipment — that part scales relatively cheaply. Traditional herbal medicine formulation does not scale the same way. Each new product or expanded production run requires master practitioners who understand both the traditional preparation methods and how to judge the quality of variable herb harvests. That expertise is the ceiling.
What external forces can significantly affect this company?
China's Belt and Road Initiative is opening regulatory doors for TCM exports into participating countries, which expands the addressable market. China's aging population is driving higher demand for traditional medicine used alongside modern healthcare. At the same time, regulators in international markets increasingly require Western-standard clinical trial evidence before approving traditional medicine products, which raises the bar for selling outside China.
Where is this company structurally vulnerable?
If the NMPA changes its rules to require Western-style clinical trials before renewing TCM certificates, the company's existing registrations — which were approved under traditional demonstration standards — would need to be re-validated under a completely different process. The practitioner-based method was never designed to produce that kind of trial data, so the link between the certificates on paper and the actual production process would be severed.
Sign in to view price data.
Sign inScreen for dividend patterns
Find other stocks with similar dividend characteristics in the screener.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph